Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain

Peptides. Mar-Apr 1990;11(2):311-31. doi: 10.1016/0196-9781(90)90088-m.


Guinea pig brain membranes depleted of mu and delta receptors by pretreatment with the site-directed acylating agents, 2-(4-ethoxybenzyl)-1- diethylaminoethyl-5-isothiocyanatobenzimidazole.HCl (BIT) and N-phenyl-N-[1-(2-(4-isothiocyanato)phenethyl)-4- piperidinyl]-propanamide.HCl (FIT), were used in this study to test the hypothesis that guinea pig brain possesses subtypes of kappa receptors. Pretreatment of membranes with either (-)-(1S,2S)-U50,488 or the kappa selective acylating agent, (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1- pyrrolidinyl)cyclohexyl]benzeneacetamide, caused a wash-resistant inhibition of kappa 1 binding sites labeled by [3H]U69,593 binding, but not kappa 2 binding sites labeled by [3H]bremazocine. Binding surface analysis of [3H]bremazocine binding resolved two binding sites, termed kappa 2 and kappa 2b, present at densities of 212 and 225 fmol/mg protein, which had low affinity for (-)-(1S,2S)-U50,488 and U69,593. The kappa 2b site had high affinity for beta-endorphin(1-31) (Kd = 5.5 nM) and [D-Ala2,D-Leu5]enkephalin (Kd = 14 nM), and lower affinity for [D-Ala2-MePhe4,Gly-ol5]enkephalin (Kd = 147 nM) and [Leu5]enkephalin (Kd = 46.0 nM). Binding surface analysis of [3H]U69,593 binding also resolved two binding sites, termed kappa 1a and kappa 1b, present at densities of 6.0 and 40.0 fmol/mg protein. The kappa 1a binding site was characterized by very high affinity for alpha-neoendorphin. Quantitative autoradiographic studies demonstrated that kappa 2a and kappa 2b binding sites are heterogeneously distributed in guinea pig brain, and that the anatomical distribution of kappa 1 binding sites reported in the literature is different from that observed in this study for the kappa 2 binding sites. Viewed collectively, these data provide evidence for four kappa receptor subtypes in guinea pig brain.

MeSH terms

  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Affinity Labels
  • Analysis of Variance
  • Animals
  • Autoradiography
  • Benzeneacetamides*
  • Benzomorphans / metabolism
  • Brain / metabolism*
  • Data Interpretation, Statistical
  • Endorphins / metabolism*
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
  • Enkephalins / metabolism
  • Guinea Pigs
  • Ligands
  • Male
  • Mathematics
  • Membranes / metabolism
  • Naltrexone / analogs & derivatives
  • Naltrexone / metabolism
  • Pyrrolidines / metabolism
  • Receptors, Opioid / metabolism*
  • Receptors, Opioid, kappa
  • Temperature


  • Affinity Labels
  • Benzeneacetamides
  • Benzomorphans
  • Endorphins
  • Enkephalins
  • Ligands
  • Pyrrolidines
  • Receptors, Opioid
  • Receptors, Opioid, kappa
  • Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
  • Naltrexone
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • 3-acetyl-6-deoxy-6-fluoronaltrexone
  • bremazocine
  • U 69593